-+ 0.00%
-+ 0.00%
-+ 0.00%

Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress

PUBT·08/06/2026 12:10:45
Listen to the news
Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress
  • Whitehawk Therapeutics outlined three lead antibody-drug conjugates, with HWK-007 and HWK-016 in Phase 1.
  • Initial Phase 1 data for HWK-007 and HWK-016 targeted for 1H 2027; HWK-206 Phase 1 start expected in Q3 2026.
  • HWK-206, a SEZ6 program in IND-enabling, is positioned for SCLC and neuroendocrine tumors; data targeted for 2H 2027.
  • Cash balance of USD 190 million as of June 30, 2026; cash runway projected into 2H 2028.
  • Pipeline expansion plans include an option with Hangzhou DAC for up to five CPT113-based ADCs, including dual-payload candidates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.